Premium
Cooperative expression of junctional adhesion molecule‐C and ‐B supports growth and invasion of glioma
Author(s) -
Tenan Mirna,
AurrandLions Michel,
Widmer Valerie,
Alimenti Alessandro,
Burkhardt Karim,
Lazeyras François,
Belkouch MarieClaude,
Hammel Philippe,
Walker Paul R.,
Duchosal Michel A.,
Imhof Beat A.,
Dietrich PierreYves
Publication year - 2010
Publication title -
glia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.954
H-Index - 164
eISSN - 1098-1136
pISSN - 0894-1491
DOI - 10.1002/glia.20941
Subject(s) - biology , glioma , microbiology and biotechnology , angiogenesis , cell adhesion molecule , cell migration , cancer research , cell , genetics
Brain invasion is a biological hallmark of glioma that contributes to its aggressiveness and limits the potential of surgery and irradiation. Deregulated expression of adhesion molecules on glioma cells is thought to contribute to this process. Junctional adhesion molecules (JAMs) include several IgSF members involved in leukocyte trafficking, angiogenesis, and cell polarity. They are expressed mainly by endothelial cells, white blood cells, and platelets. Here, we report JAM‐C expression by human gliomas, but not by their normal cellular counterpart. This expression correlates with the expression of genes involved in cytoskeleton remodeling and cell migration. These genes, identified by a transcriptomic approach, include poliovirus receptor and cystein‐rich 61, both known to promote glioma invasion, as well as actin filament associated protein, a c‐Src binding partner. Gliomas also aberrantly express JAM‐B, a high affinity JAM‐C ligand. Their interaction activates the c‐Src proto‐oncogene, a central upstream molecule in the pathways regulating cell migration and invasion. In the tumor microenvironment, this co‐expression may thus promote glioma invasion through paracrine stimuli from both tumor cells and endothelial cells. Accordingly, JAM‐C/B blocking antibodies impair in vivo glioma growth and invasion, highlighting the potential of JAM‐C and JAM‐B as new targets for the treatment of human gliomas. © 2009 Wiley‐Liss, Inc.